Efficacy Data in Active PsA | TREMFYA® (guselkumab) HCP

IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)
1 IN 2 PATIENTS EXPERIENCED COMPLETE RESOLUTION OF ENTHESITIS AT WEEK 241

View Study Design

POOLED DATA FROM DISCOVER 1 AND DISCOVER 2: RESOLUTION OF ENTHESITIS (LEI SCORE=0) AT WEEK 24 (NRI ANALYSIS)*†‡

ENTHESITIS

*Among patients with enthesitis (Leeds Enthesitis Index [LEI]) at baseline.

Through Week 24, patients were considered to be nonresponders after meeting treatment failure criteria: discontinued study agent due to any reason, terminated study participation for any reason, initiated or increased the dose of DMARDs or oral corticosteroids over baseline for PsA, or initiated protocol-prohibited medications/therapies for PsA. After Week 24, treatment failure rules were not applied.

Patients with missing data were considered nonresponders.

 

IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)
NEARLY 6 OUT OF 10 PATIENTS EXPERIENCED COMPLETE RESOLUTION OF DACTYLITIS AT WEEK 241

POOLED DATA FROM DISCOVER 1 AND DISCOVER 2: RESOLUTION OF DACTYLITIS (DACTYLITIS SCORE=0) AT WEEK 24 (NRI ANALYSIS)||¶#​

DACTYLITIS

||​Among patients with dactylitis at baseline.

Through Week 24, patients were considered to be nonresponders after meeting treatment failure criteria: discontinued study agent due to any reason, terminated study participation for any reason, initiated or increased the dose of DMARDs or oral corticosteroids over baseline for PsA, or initiated protocol-prohibited medications/therapies for PsA. After Week 24, treatment failure rules were not applied.

#Patients with missing data were considered nonresponders.

 

Reference: 1. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER 2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;20(30263):1-11.